Concord Biotech announced the successful completion of an inspection conducted by Brazil's National Health Surveillance Agency (ANVISA) at its active pharmaceutical ingredient (API) manufacturing facility in Limbasi. According to the company's regulatory filing, the inspection was carried out between 8 June and 12 June 2026 and concluded successfully. The company stated that this achievement marks a significant milestone in their global growth journey, reinforcing their commitment to the highest standards of quality and regulatory excellence.
As reported by Capital Market News, the successful completion of the ANVISA inspection advances Concord Biotech's international expansion strategy by enhancing access to one of the world's largest pharmaceutical markets. The achievement broadens the reach of their high-quality APIs across key geographies, strengthening their global manufacturing and regulatory footprint. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations, maintaining a presence in more than 70 countries worldwide. This successful inspection is anticipated to enhance the company's ability to supply high-quality APIs to key global geographies, reinforcing its position in the international pharmaceutical landscape.
According to Capital Market News, Concord Biotech's consolidated net profit declined 36.75% to ₹88.79 crore on a 24.15% drop in revenue from operations to ₹326.07 crore in Q4 FY26 over Q4 FY25. The company's financial performance reflects the challenges faced in the pharmaceutical sector during the reporting period, with both profitability and revenue metrics showing significant year-over-year declines.
